CN101502571B - 一种活血、镇痛和抗炎的药物和应用 - Google Patents
一种活血、镇痛和抗炎的药物和应用 Download PDFInfo
- Publication number
- CN101502571B CN101502571B CN2009100476233A CN200910047623A CN101502571B CN 101502571 B CN101502571 B CN 101502571B CN 2009100476233 A CN2009100476233 A CN 2009100476233A CN 200910047623 A CN200910047623 A CN 200910047623A CN 101502571 B CN101502571 B CN 101502571B
- Authority
- CN
- China
- Prior art keywords
- group
- percent
- blood circulation
- rat
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 210000004369 blood Anatomy 0.000 title abstract description 19
- 239000008280 blood Substances 0.000 title abstract description 19
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 11
- 230000000146 antalgic effect Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 47
- 230000017531 blood circulation Effects 0.000 claims abstract description 20
- 241000218176 Corydalis Species 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 64
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 239000012567 medical material Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 239000003463 adsorbent Substances 0.000 claims description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 10
- 241000180649 Panax notoginseng Species 0.000 claims description 10
- 208000012287 Prolapse Diseases 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 230000036592 analgesia Effects 0.000 claims description 9
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 8
- 230000001741 anti-phlogistic effect Effects 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 230000008021 deposition Effects 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000005325 percolation Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 13
- 208000002193 Pain Diseases 0.000 abstract description 9
- 230000036407 pain Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 206010050296 Intervertebral disc protrusion Diseases 0.000 abstract description 2
- 241000227129 Aconitum Species 0.000 abstract 2
- 241000157282 Aesculus Species 0.000 abstract 2
- 241000893536 Epimedium Species 0.000 abstract 2
- 239000009759 San-Chi Substances 0.000 abstract 2
- 235000018905 epimedium Nutrition 0.000 abstract 2
- 235000010181 horse chestnut Nutrition 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 description 101
- 241000700159 Rattus Species 0.000 description 82
- 239000009157 yaotongning Substances 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 38
- 239000000725 suspension Substances 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 26
- 230000008961 swelling Effects 0.000 description 25
- 210000005012 myelin Anatomy 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 238000005303 weighing Methods 0.000 description 22
- 238000011552 rat model Methods 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 208000007536 Thrombosis Diseases 0.000 description 19
- 229960001138 acetylsalicylic acid Drugs 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 239000000872 buffer Substances 0.000 description 18
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 17
- 210000005036 nerve Anatomy 0.000 description 17
- 230000001537 neural effect Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 239000000835 fiber Substances 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 13
- 239000002662 enteric coated tablet Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 206010016654 Fibrosis Diseases 0.000 description 10
- 206010040007 Sense of oppression Diseases 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000004761 fibrosis Effects 0.000 description 10
- 230000003387 muscular Effects 0.000 description 10
- 230000037040 pain threshold Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 208000000114 Pain Threshold Diseases 0.000 description 7
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 239000012362 glacial acetic acid Substances 0.000 description 7
- 238000005286 illumination Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- 229960002275 pentobarbital sodium Drugs 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 238000009423 ventilation Methods 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 210000000578 peripheral nerve Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000003371 toe Anatomy 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 206010014025 Ear swelling Diseases 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000005021 gait Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000036473 myasthenia Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- KFGOFTHODYBSGM-IJCBKZNRSA-N 6-Keto-prostaglandin F1a Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O KFGOFTHODYBSGM-IJCBKZNRSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 description 2
- -1 Semen Strychni Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007978 cacodylate buffer Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- AXNVHPCVMSNXNP-OXPBSUTMSA-N Aescin Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(C[C@H]14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AXNVHPCVMSNXNP-OXPBSUTMSA-N 0.000 description 1
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000195622 Astasia Species 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 208000018650 Intervertebral disc disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000003164 cauda equina Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000018180 degenerative disc disease Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003666 myelinated nerve fiber Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 206010030899 opisthotonus Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940011971 pentobarbital sodium 4 mg/ml Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100476233A CN101502571B (zh) | 2009-03-16 | 2009-03-16 | 一种活血、镇痛和抗炎的药物和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100476233A CN101502571B (zh) | 2009-03-16 | 2009-03-16 | 一种活血、镇痛和抗炎的药物和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101502571A CN101502571A (zh) | 2009-08-12 |
CN101502571B true CN101502571B (zh) | 2012-07-04 |
Family
ID=40975032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100476233A Expired - Fee Related CN101502571B (zh) | 2009-03-16 | 2009-03-16 | 一种活血、镇痛和抗炎的药物和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101502571B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104027747A (zh) * | 2014-06-28 | 2014-09-10 | 王用涛 | 一种治疗气滞血瘀型痛经的药酒及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1312098A (zh) * | 2001-02-21 | 2001-09-12 | 杨玉明 | 一种治疗风湿、类风湿等痹症的药酒 |
CN1362068A (zh) * | 2000-12-30 | 2002-08-07 | 李毅 | 类风湿胶囊 |
CN101284057A (zh) * | 2007-04-13 | 2008-10-15 | 李毅 | 腰痛宁药物及其制备方法 |
-
2009
- 2009-03-16 CN CN2009100476233A patent/CN101502571B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1362068A (zh) * | 2000-12-30 | 2002-08-07 | 李毅 | 类风湿胶囊 |
CN1312098A (zh) * | 2001-02-21 | 2001-09-12 | 杨玉明 | 一种治疗风湿、类风湿等痹症的药酒 |
CN101284057A (zh) * | 2007-04-13 | 2008-10-15 | 李毅 | 腰痛宁药物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101502571A (zh) | 2009-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101862351A (zh) | 没食子有效部位在制备抗溃疡性结肠炎的药物的用途 | |
CN102861287A (zh) | 一种治疗湿热下注淤血型糖尿病足的中药组合物及其制备方法 | |
CN102100825A (zh) | 治疗疼痛的中药组合物及其制备方法 | |
CN102266514A (zh) | 一种治疗急、慢性胃炎的中药组合物及其制备方法 | |
CN101502571B (zh) | 一种活血、镇痛和抗炎的药物和应用 | |
CN101129972B (zh) | 一种中药组合物、其制备方法及其用途 | |
CN104398962A (zh) | 一种治疗脾肾两虚型腰肌劳损的中药组合物及其制备方法 | |
CN101804083B (zh) | 松花粉及其提取物在治疗炎症性肠病中的用途及该提取物的制备方法 | |
CN113116976A (zh) | 一种中药组合物在制备预防或治疗消化内科疾病药物中的应用 | |
CN103386101B (zh) | 一种治疗非特异性膀胱炎的中药制剂及其制备方法 | |
CN101884664B (zh) | 一种防治类风湿性关节炎的药物组合物及其制备方法 | |
CN104971271A (zh) | 一种治疗瘀湿化热型前列腺增生的药物及制备方法 | |
CN105232759A (zh) | 一种治疗鼻炎的药物组合物及其制备方法 | |
CN101249236B (zh) | 一种治疗癫痫的中西医药结合制剂 | |
CN103585275B (zh) | 用于治疗风湿骨病的中药组合物及中成药的制备方法和应用 | |
CN115845003B (zh) | 一种中药组合物在制备治疗关节炎药物中的应用 | |
CN107303330A (zh) | 一种防治痛风的中药组合物及其制备方法与应用 | |
CN102335304B (zh) | 一种祛风燥湿活血止痛的中药组合物及其制备方法 | |
Hailume | In vitro anticancer and anti-inflammatory potential of Tian immune booster | |
CN102228512B (zh) | 一种治疗类风湿关节炎的药物及制备方法 | |
CN107050359A (zh) | 治疗慢性盆腔炎性疾病后遗症的壮药制剂及其制备方法 | |
CN104257702B (zh) | 舒筋草总生物碱的新用途 | |
CN105456608A (zh) | 一种治疗风湿性关节炎的中药 | |
Liu et al. | Network pharmacology combined with an animal model to reveal the material basis and mechanism of Amomum villosum in alleviating constipation in mice | |
CN104398888A (zh) | 一种治疗肾阴虚型腰肌劳损的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU BAICAOTANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI NORMAL UNIVERSITY Effective date: 20150529 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200234 XUHUI, SHANGHAI TO: 225300 TAIZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150529 Address after: 225300, No. 5, Mu Lu, pharmaceutical hi tech Zone, Jiangsu, Taizhou Patentee after: Jiangsu baicaotang Pharmaceutical Co., Ltd. Patentee after: Shanghai new Kang Pharmaceutical Co., Ltd. Address before: 200234 Xuhui District, Guilin Road, No. 100, Patentee before: Shanghai Normal University Patentee before: Shanghai Xinkang Pharmaceutical Factory |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170608 Address after: 200234 Xuhui District, Guilin Road, No. 100, Patentee after: Shanghai Normal University Address before: 225300, No. 5, Mu Lu, pharmaceutical hi tech Zone, Jiangsu, Taizhou Co-patentee before: Shanghai new Kang Pharmaceutical Co., Ltd. Patentee before: Jiangsu baicaotang Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 Termination date: 20190316 |
|
CF01 | Termination of patent right due to non-payment of annual fee |